1

Identity

Roche Farma, S.A.

A08023145

€796M

Amount awarded, solo awards 2016–2026

Amount awarded by year
YearAmountDistribution
2026*€226.9M
2025€168.1M
2024€114.7M
+ regional platforms
2023€70.2M
2022€89.2M
2021€46.5M
2020€14.7M
2019€63.2M
2018€0.6M
2017€2.1M
2016€<0.1M
*2026: data to 31 October · 184 contracts in 2026 · Since 2024 this also includes data from regional platforms. · Solo awards, excluding JVs · Framework agreements at €0 · €M
982
Contracts (lots)
across 632 tenders
53
Buyers
94%
Single bidder
11
Awards in UTEs
not in the total

In figures

Volume

Between 2016 and 2026 it won 982 contracts worth €796M on its own, with 53 buyers. Its 11 joint-venture (UTE) contracts are shown separately.

Price

It has fewer than 3 comparable awards, too few to compute its median discount.

Competition

Since 2024, 0% of its comparable value was won with a discount and against other bidders. It was the only bidder in 94% of its contracts (2016–2026).

Renewals

86 contracts (€50.2M) come up for tender again in the next 24 months.

A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Roche Farma, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Roche Farma, S.A.'s share.

Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage

2

Its discounts

The discount at which it wins contested contracts, year by year.

Only 2 contested awards can be compared — not enough to read how it prices. Of its 982 contracts, 620 are call-offs under framework agreements and 162 were awarded without competition (negotiated without publicity or direct award).

Framework call-offs 620 · Single bidder 46 · Non-competitive procedure 162 · No comparable budget 152 · Contested, comparable 2

Where it wins, and at what discount

In the report · these discounts, one by one

Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.

Request the report →

Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.

3

How it wins

Whether it wins with or without competition.

Competition and pricing

84% of the comparable value since 2024 (€25.3M of €30.0M) was won at the tender price and without other bidders. €4.72M (16%) was awarded with a discount and without other bidders.

With a discount
16%
single bidder · 12 · €4.72M
0%
multiple bidders · 0
At the tender price
84%
single bidder · 25 · €25.3M
0%
multiple bidders · 0

Comparable: 37 awards with a published budget and bidder count (€30.0M of €510M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.

Award procedure

Between 2016 and 2026, 69.0% of the value was awarded through negotiated without publicity procedure (48.6% of contracts); followed by Based on a framework agreement (9.7%) and Open (9.0%).

Negotiated without publicity · 69.0%
Open
Negotiated with publicity
Based on a framework agreement
Negotiated without publicity
Other
4

Upcoming tenders and main buyers

When its contracts come back and who it sells to.

Who they sell to
BuyerContractsValue, €Period
OSAKIDETZA - Servicio Vasco de Salud -Director General31155 M2024–2026
Gerencia de Servicio Sanitarios de Fuerteventura571135 M2018–2026
Subsecretaría de la Consellería de Sanidad y Salud Pública22110 M2020–2026
Servicio Andaluz de Salud4382 M2024–2026
Dirección General de Planificación Económica3346 M2018–2026

and 48 more buyers

Sector activity
Top CPV codes — the EU classification system that identifies the type of works, services or supplies covered by each contract.

Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 966 contracts).

Medical & pharmaceuticals
100.0%966 contracts
5

Recent awards

The evidence behind every insight in the report.

Latest 5 completed contracts (of 323)
Contracts whose expected completion date has passed.
DateContractBuyerBiddersValue
03/07/2026Suministro de medicamentos de uso humano tipo II (Exclusivos), con destino al Servicio de Farmacia …Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria1€85.7k
08/06/2026cpca 1º cbam roche farma, s.a. exp. 578/2025 suministro medicamento exclusivos cca: +6.i+e0q8j, am …Servicio Andaluz de Salud1€1.87M
03/06/2026Suministro de medicamentos de uso humano tipo ii (exclusivos), lote 160, con destino al servicio de…Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria1€5.61k
17/04/2026Suministro de 10.000 envases de Baloxavir (Xofluza) para la Reserva Estratégica NacionalDirección del Instituto Nacional de Gestión Sanitaria (INGESA)1€433k
14/04/20261º cbam exp. 771/2025 am con varias empresas por el que se fijan las condiciones para el suministro…Servicio Andaluz de Salud1€159k
Full report on Roche Farma, S.A.
Includes: its discount by buyer and sector · winning discounts by buyer and year · how it wins with each buyer · contract renewal calendar. The complete register of its awards in the last three full calendar years and the current year to date, in Excel.
€50 + VAT · VAT is calculated at payment according to your country. You will receive it in PDF and Excel by email within one working day. Every report is reviewed by a person before it is sent to you.
Order the report